- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Practices Have to Grapple With the Logistics of Insurers’ Preferred Biosimilars: Dr Lalan Wilfong
While commercial payers have been engaged with the shift to biosimilars, they all have their own preferred biosimilar, which makes it challenging for practices, explained Lalan Wilfong, MD, vice president of payer relations & practice transformation at The US Oncology Network.
While commercial payers have been engaged with the shift to biosimilars, they all have their own preferred biosimilar, which makes it challenging for practices, explained Lalan Wilfong, MD, vice president of Payer Relations & Practice Transformation at The US Oncology Network.
Transcript
What has been your experience with commercial payer contracts on the use of biosimilars? Are they encouraging biosimilar use?
In our experience, commercial payers are wanting to move to biosimilars. Many of them—because of what they do and having to be held accountable to their employers and other people who are buying services from the insurers—they do want to utilize services that lower the cost of care. We have seen a shift to biosimilars for our commercial payers.
I’ll say the challenge with them is that each one of them want to pick a winner that they like, which makes it extremely challenging for a practice to have to shift gears for every patient that walks in the door and use the insurer’s “preferred biosimilar” versvsus just using biosimilars. And we always advocate for physician choice and that if we're going to use biosimilars, let us be able to pick the biosimilar that we want to use so it's much easier on a practice to be able to manage their patient population, rather than having to switch gears with every single patient that walks in the door.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Bridging Care Gaps With a Systemwide Value-Based Care Strategy
March 29th 2025Mapping care management needs by defining patient populations and then stratifying them according to risk and their needs can help to spur the transformation of a siloed health care system into an integrated system that is able to better provide holistic, value-based care despite the many transitions that continue among hospital, primary, specialty, and community care environments.
Read More
